Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCAR-T in refractory systemic lupus erythematosus
NCT07274059Phase 1Recruiting
- Sponsor
- Ucello Biotechnology
- Start
- Mar 2025
- Primary completion
- Dec 2035
- Countries
- 1
01
Overview
Phase 1, open-label trial of UC-101 in systemic lupus erythematosus (SLE), sponsored by Ucello Biotechnology. Primary endpoints: Dose limited toxicity at 28 days and Adverse events at 2 months. Started Mar 2025; status: recruiting.
02
Drugs
UC-101
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07274059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07274059.